Developments in the treatment of carcinoid syndrome - impact of telotristat.

about

Developments in the treatment of carcinoid syndrome - impact of telotristat.

Item

http://www.wikidata.org/entity/Q52674898

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Developments in the treatment of carcinoid syndrome - impact of telotristat.

@en

Developments in the treatment of carcinoid syndrome - impact of telotristat.

@nl

type

Item

label

Developments in the treatment of carcinoid syndrome - impact of telotristat.

@en

Developments in the treatment of carcinoid syndrome - impact of telotristat.

@nl

prefLabel

Developments in the treatment of carcinoid syndrome - impact of telotristat.

@en

Developments in the treatment of carcinoid syndrome - impact of telotristat.

@nl

P1476

Developments in the treatment of carcinoid syndrome - impact of telotristat.

@en

P2093

David L Chan

http://www.w3.org/2001/XMLSchema#string

Simron Singh

http://www.w3.org/2001/XMLSchema#string

P2860

Genetic disruption of both tryptophan hydroxylase genes dramatically reduces serotonin and affects behavior in models sensitive to antidepressants.

Tetrahydropterin-dependent amino acid hydroxylases

Synthesis of serotonin by a second tryptophan hydroxylase isoform

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

Pharmacological reduction of mucosal but not neuronal serotonin opposes inflammation in mouse intestine.

Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs.

Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide

The serotonin signaling system: from basic understanding to drug development for functional GI disorders.

The pathophysiological consequences of somatostatin receptor internalization and resistance.

American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.

P304

323-329

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/TCRM.S126143

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-02-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29503551

http://www.w3.org/2001/XMLSchema#string

P932

5824756

http://www.w3.org/2001/XMLSchema#string